Sign in

Yaron Eitan

Director at Marpai
Board

About Yaron Eitan

Technology entrepreneur and investor with 30+ years’ experience; Chairman of Marpai’s Board since April 1, 2021, transitioning to non-chair Director following the 2025 annual meeting . Age 69 as of the 2025 record date; holds a B.S. from Haifa University and an M.B.A. from The Wharton School . External board service includes Director at Nano Dimension Ltd. (Nasdaq: NNDM) since April 2020; prior Executive Chairman of DeepCube Ltd. (2017–2021) . Core credentials include deep learning/AI commercialization and company-building across private and public tech firms .

Past Roles

OrganizationRoleTenureCommittees/Impact
Marpai, Inc.Chairman of the Board; DirectorChairman since Apr 1, 2021; will remain Director after 2025 meeting Board leadership transition to CEO Damien Lamendola as Chair post-2025 meeting
DeepCube Ltd.Executive ChairmanFeb 2017 – Mar 2021 Oversight of deep learning company; prior to acquisition/industry activity

External Roles

OrganizationRoleTenureNotes
Nano Dimension Ltd. (Nasdaq: NNDM)DirectorSince Apr 2020 Public company directorship
Emporus Technologies, Ltd.ChairmanSince Feb 2020 Deep learning company leadership
Selway Capital LLCManaging PartnerSince Dec 2008 Investment/merchant banking role

Board Governance

  • Committee assignments: Not listed as a member of the Audit Committee (Shiv–Chair, DiClaudio, Calabrese) or Compensation Committee (DiClaudio–Chair, Pons) .
  • Chair role: Served as Chairman since April 1, 2021; stepping down as Chair following the 2025 annual meeting; remains a Director .
  • Independence: Company states independent directors are Sagiv Shiv, Colleen DiClaudio, Robert Pons, and Jennifer Calabrese; Eitan is not named as independent (implies non-independence) .
  • Attendance/engagement: Attended the last annual stockholders’ meeting (with CEO Lamendola) . Audit Committee met four times in FY2024; Compensation Committee met four times in FY2024 and six times in FY2023 (Eitan is not a member) .
  • Nominating/governance: No standing nominating committee; independent directors (Shiv, DiClaudio) recommend nominees to the Board .

Fixed Compensation (Directors)

ComponentAmount/StructureEffective DatesNotes
Annual cash retainer (independent directors)$50,000/year (payable quarterly) Approved Mar 20, 2022; terminated Dec 7, 2023 Cash retainer eliminated in Dec 2023; replaced by equity RSUs
Meeting feesNone disclosedN/ANo board/committee meeting fees disclosed

Performance Compensation (Directors)

Equity ElementGrant Size/TermsVestingEffective/Approvals
RSUs (standard)50,000 RSUs for independent directors; 60,000 RSUs for committee chairs and the Chairman 30% on grant; 35% after 1 year; 35% after 2 years Approved Dec 7, 2023 (policy); January/May 2024 issuances tied to plan approvals
Tenure-based RSUs (additional)7,500 RSUs per year of service for each independent director; 5,000 RSUs per year for each non-independent director Not specified beyond standard plan vesting constructsApproved May 24, 2024
Special one-time grant100,000 RSUs to one director for uplisting project; 50,000 vested 12/31/2024; 50,000 vest upon successful uplisting (currently not probable) As notedApproved Jun 18, 2024

Performance metrics: Director equity is time-based; no disclosed performance (revenue/EBITDA/TSR/ESG) metrics apply to director RSUs .

Other Directorships & Interlocks

CompanyExchangeRolePotential Interlock/Conflict
Nano Dimension Ltd.NasdaqDirector since Apr 2020 No disclosed customer/supplier overlap with Marpai in proxy
Emporus Technologies, Ltd.PrivateChairman since Feb 2020 Technology/AI focus; no disclosed related-party deals with Marpai
Selway Capital LLCPrivateManaging Partner since Dec 2008 Investment firm; no disclosed related-party deals with Marpai in 2024–2025 proxy

Expertise & Qualifications

  • Technology/AI and entrepreneurship (Chairman roles at DeepCube and Emporus) .
  • Finance/investing (Managing Partner at Selway Capital) .
  • Education: B.S. (Haifa University), M.B.A. (Wharton) .

Equity Ownership

CategoryDetails
Total beneficial ownership883,810 shares; 5.3% of outstanding as of July 1, 2025
Common shares (direct)768,073 shares
Warrants56,948 warrants @ $31.60, expiring Feb 9, 2026
Stock options62,500 options @ $4.44 (58,789 vested)
Pledging/HedgingNo pledging disclosed; company insider trading policy prohibits short sales, options, and hedging transactions for directors and covered persons .

Insider Trades and Related Transactions

DateTransactionSecuritiesPrice/TermsNotes
Dec 5, 2024Insider private placementPurchased 110,619 shares of common stock$1.13 per shareParticipated with other insiders (CFO, President)
Jan 16, 2024Insider private placement (aggregate for insiders)1,322,100 shares issued to insiders including Eitan and Pons$0.9201 per shareIndividual allocation to Eitan not itemized in proxy
Consulting fees (historical)Management consulting agreement$15,000/mo; increased to $22,750/mo (Apr 2021–Mar 31, 2022 or termination)Agreement ended; superseded by employment in 2023Related-party consulting; $88k total in 2023; $0 in 2024
Employment agreement (historical)Entered July 2023$168,000 annual salaryAt-willThis employment relationship contributes to non-independence

Director Compensation Mix and Structure

  • Shift from cash to equity: Cash retainers for independent directors ($50,000/year) terminated Dec 7, 2023 in favor of RSU-based compensation (50,000 RSUs for independent directors; 60,000 RSUs for chairs/Chairman; time-vested) .
  • Additional tenure-based RSUs per year of service added May 24, 2024 (7,500 RSUs independent; 5,000 RSUs non-independent) .

Employment & Contracts (Relevance to Independence)

  • Eitan’s consulting agreement (Apr 2021–Mar 2022) transitioned to an employment agreement (July 2023) with $168,000 salary (at-will). The company’s 2025 proxy lists independent directors and does not include Eitan, indicating he is not considered independent under Nasdaq rules .

Risk Indicators & Red Flags

  • Independence: Not listed among independent directors in 2024 and 2025 proxies (governance independence concern) .
  • Related-party exposure: Prior consulting agreement and subsequent employment agreement with the company; insider participation in private placements, including a disclosed December 2024 purchase (alignment + potential conflict) .
  • Hedging/Pledging: Insider trading policy prohibits hedging/derivative transactions; no pledging disclosed (positive) .
  • Legal/Regulatory: Company states directors have not been involved in material legal proceedings as defined by Item 401(f) (positive) .

Governance Assessment

  • Alignment: Material personal ownership (5.3%), additional options/warrants, and participation in financing suggest strong financial alignment with shareholders .
  • Independence/Conflicts: Not identified as independent; history of consulting and employment arrangements with Marpai limits independence, and insider financings can create perceived conflicts (mitigated by related-party review under Audit Committee charter) .
  • Board effectiveness: Not on Audit or Compensation Committees; attended last annual meeting; board is adding structure (committee activity; considering future governance/nomination committee) .
  • Overall: Strong operating/AI background and ownership stake benefit strategic guidance and alignment; however, non-independence and related-party history warrant monitoring for conflicts and ensure robust recusal and Audit Committee oversight on any transactions .